| Budget Amount *help |
¥194,740,000 (Direct Cost: ¥149,800,000、Indirect Cost: ¥44,940,000)
Fiscal Year 2014: ¥36,140,000 (Direct Cost: ¥27,800,000、Indirect Cost: ¥8,340,000)
Fiscal Year 2013: ¥38,090,000 (Direct Cost: ¥29,300,000、Indirect Cost: ¥8,790,000)
Fiscal Year 2012: ¥40,040,000 (Direct Cost: ¥30,800,000、Indirect Cost: ¥9,240,000)
Fiscal Year 2011: ¥39,650,000 (Direct Cost: ¥30,500,000、Indirect Cost: ¥9,150,000)
Fiscal Year 2010: ¥40,820,000 (Direct Cost: ¥31,400,000、Indirect Cost: ¥9,420,000)
|
|---|
| Outline of Final Research Achievements |
Two tumor-associated antigens, KIF20A- and GPC3-derived long peptides (LPs) that can be presented to CD4+ type 1 T helper (Th1) cells through multiple HLA class II molecules frequently observed in the Japanese population were identified. Using HLA-A2/A24-transgenic mice, vaccination of those LPs encompassing short peptides (SPs) that can activate the tumor-reactive cytotoxic T lymphocytes (CTL) more efficiently induced CTLs than SP-vaccination did, suggesting the effectiveness of LPs for the improvement of anti-tumor immunotherapy. In addition, it was observed that among the patients vaccinated several times with SP derived from GPC3, an oncofetal tumor-associated antigen highly and frequently expressed in the hapatocellular carcinoma, those who induced Th cell responses specific to GPC3-LPs exhibited significantly longer overall survival time.
|
